Citi lowered the firm’s price target on GSK (GSK) to 2,100 GBp from 2,250 GBp and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Earnings Call Highlights Specialty Strength, H2 Upside
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- Trump Trade: Microsoft, Google agree to U.S. security reviews of AI models
- AnaptysBio price target lowered to $93 from $95 at Piper Sandler
- Alector to discontinue PROGRESS-AD trial of nivisnebart